UA101961C2 - Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида - Google Patents

Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида

Info

Publication number
UA101961C2
UA101961C2 UAA201005713A UAA201005713A UA101961C2 UA 101961 C2 UA101961 C2 UA 101961C2 UA A201005713 A UAA201005713 A UA A201005713A UA A201005713 A UAA201005713 A UA A201005713A UA 101961 C2 UA101961 C2 UA 101961C2
Authority
UA
Ukraine
Prior art keywords
methylpyrrolidin
benzimidazole
carboxamide
crystalline form
disease
Prior art date
Application number
UAA201005713A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Лоуренс КОЛАЦКОВСКИ
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA101961(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA101961C2 publication Critical patent/UA101961C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201005713A 2007-10-12 2008-10-10 Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида UA101961C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12
PCT/US2008/079441 WO2009049111A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Publications (1)

Publication Number Publication Date
UA101961C2 true UA101961C2 (xx) 2013-05-27

Family

ID=40210712

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201005713A UA101961C2 (xx) 2007-10-12 2008-10-10 Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
UAA201300752A UA113277C2 (xx) 2007-10-12 2008-10-10 Комбінація кристалічної форми1 2-((r)-2-метилпіролідин-2-іл)-1н-бензімідазол-4-карбоксаміду та протиракового лікарського засобу

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201300752A UA113277C2 (xx) 2007-10-12 2008-10-10 Комбінація кристалічної форми1 2-((r)-2-метилпіролідин-2-іл)-1н-бензімідазол-4-карбоксаміду та протиракового лікарського засобу

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20100090769A (enExample)
CN (2) CN101821270A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Also Published As

Publication number Publication date
CN105367554A (zh) 2016-03-02
DK2722046T3 (en) 2017-03-20
BRPI0816221A8 (pt) 2015-09-22
PT2722046T (pt) 2017-03-15
CR11368A (es) 2010-10-25
NZ583209A (en) 2012-06-29
US20150148392A1 (en) 2015-05-28
AU2008310781B2 (en) 2013-03-28
GT201000080A (es) 2012-04-03
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
CO6280493A2 (es) 2011-05-20
CA3006332A1 (en) 2009-04-16
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2011500589A (ja) 2011-01-06
US8372987B2 (en) 2013-02-12
PL2722046T3 (pl) 2017-06-30
MX2010003772A (es) 2010-04-21
ZA201002090B (en) 2011-11-30
SG185297A1 (en) 2012-11-29
AU2008310781A1 (en) 2009-04-16
MX350019B (es) 2016-12-09
EP2722046A1 (en) 2014-04-23
ECSP10010150A (es) 2010-06-29
CA2696424C (en) 2018-07-10
RU2476434C2 (ru) 2013-02-27
EP2722046B1 (en) 2016-12-21
PA8798401A1 (es) 2009-05-15
US8835647B2 (en) 2014-09-16
US20140024838A1 (en) 2014-01-23
KR20100090769A (ko) 2010-08-17
KR20160039312A (ko) 2016-04-08
MY156691A (en) 2016-03-15
US20130123317A1 (en) 2013-05-16
JP2017071618A (ja) 2017-04-13
UA113277C2 (xx) 2017-01-10
CA2696424A1 (en) 2009-04-16
TWI422588B (zh) 2014-01-11
CN101821270A (zh) 2010-09-01
US9580410B2 (en) 2017-02-28
JP2019001811A (ja) 2019-01-10
ES2620299T3 (es) 2017-06-28
JP2014237659A (ja) 2014-12-18
DOP2010000099A (es) 2017-04-30
BRPI0816221A2 (pt) 2015-06-16
RU2010116397A (ru) 2011-11-20
WO2009049111A1 (en) 2009-04-16
RU2012147692A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200900767A1 (ru) Антагонистические антитела против ephb3
BRPI0717753A2 (pt) Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0808246A2 (pt) "fralda descartável".
EA201100255A1 (ru) 5-алкинилпиримидины
FR2932486B1 (fr) Procede de preparation d'un polyamideimide, polyamideimide et composition comprenant ce polyamideimide.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA201100254A1 (ru) Новые соединения
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
UA99719C2 (ru) Вакцина для собак против болезни лайма
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida